NCT02293161View on ClinicalTrials.gov

Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 11, 2014

Primary Completion Date

September 1, 2015

Study Completion Date

September 1, 2015

Conditions
Autoimmune Diseases
Interventions
DRUG

GSK2618960

GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo

DRUG

Placebo

It is Sodium Chloride Intravenous Infusion

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY